A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer

Trial Profile

A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Periampullary cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors BIND Therapeutics
  • Most Recent Events

    • 04 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 09 Nov 2015 Results (n=28), presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
    • 09 Nov 2015 Results of pooled analysis from this and other two phase II trials (n=110), presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top